Abstract |
The Hippo pathway is a highly conserved signalling route involved in organ size regulation. The final effectors of this pathway are two transcriptional coactivators, yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (WWTR1 or TAZ). Previously, we showed aberrant activation of the Hippo pathway in autosomal-dominant polycystic kidney disease ( ADPKD), suggesting that YAP/TAZ might play a role in disease progression. Using antisense oligonucleotides (ASOs) in a mouse model for ADPKD, we efficiently down-regulated Yap levels in the kidneys. However, we did not see any effect on cyst formation or growth. Moreover, the expression of YAP/TAZ downstream targets was not changed, while WNT and TGF-β pathways' downstream targets Myc, Acta2 and Vim were more expressed after Yap knockdown. Overall, our data indicate that reducing YAP levels is not a viable strategy to modulate PKD progression.
|
Authors | Chiara Formica, Sandra Kunnen, Johannes G Dauwerse, Adam E Mullick, Kyra L Dijkstra, Marion Scharpfenecker, Dorien J M Peters, DIPAK Consortium |
Journal | Journal of cellular and molecular medicine
(J Cell Mol Med)
Vol. 24
Issue 15
Pg. 8876-8882
(08 2020)
ISSN: 1582-4934 [Electronic] England |
PMID | 32592332
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. |
Chemical References |
- Adaptor Proteins, Signal Transducing
- YAP-Signaling Proteins
- Yap1 protein, mouse
- protein kinase D
- Protein Kinase C
|
Topics |
- Adaptor Proteins, Signal Transducing
(genetics)
- Animals
- Cell Line
- Disease Models, Animal
- Female
- Gene Expression Regulation
- Genetic Association Studies
- Immunohistochemistry
- Mice
- Mice, Knockout
- Mutation
- Phenotype
- Polycystic Kidney Diseases
(diagnosis, genetics)
- Protein Kinase C
(genetics)
- YAP-Signaling Proteins
|